Q2 2026 Qiagen NV Earnings Call Transcript
Key Points
- Qiagen NV (QGEN) exceeded its Q2 2026 outlook for both net sales and adjusted EPS, with sales of $535 million and adjusted EPS of $0.62 at CER.
- Growth pillars delivered 5% growth at CER, with Sample Technologies up 9%, QIAcuity achieving double-digit growth, and QDI performing well.
- QuantiFERON returned to growth in Q2, with solid demand across most testing groups offsetting the decline in US immigration testing.
- The company maintained a high level of profitability, with an adjusted operating income margin of 29.4% and strong cash flow generation.
- Qiagen NV (QGEN) is making progress on new product launches, including QIAsymphony Connect, QIAsprint Connect, and the upcoming QIAmini, which are expected to drive growth in the second half.
- The company reaffirmed its full-year 2026 outlook, expecting stronger growth in H2 driven by easing comparisons and new product contributions.
- Qiagen NV (QGEN) increased its annual dividend by 40% to $0.35 per share, reflecting strong financial flexibility and shareholder returns.
- The partnership with DiaSorin and Inpeco for a fully automated QuantiFERON workflow is on track for launch in H2 2027, with high customer interest.
- QIAstat-Dx is expanding its menu with new BCID panels for bloodstream infections, which are expected to receive FDA approval by year-end.
- The collaboration with NVIDIA to combine curated biomedical knowledge with AI is expected to accelerate drug discovery and enhance QDI offerings.
- Qiagen NV (QGEN) experienced a decline in QIAstat-Dx sales of 7% at CER due to a challenging prior year comparison in respiratory testing.
- PCR and nucleic acid amplification sales declined 8% at CER, impacted by weaker OEM demand despite QIAcuity's growth.
- The company faces ongoing headwinds from reduced US immigration testing demand for QuantiFERON, which led to a $35 million revenue adjustment.
- Sales in the EMEA and Asia Pacific regions declined 2% at CER, with notable weakness in Germany, France, Italy, and China.
- The adjusted gross margin decreased to 66.2% from 66.7% in the prior year period due to changes in product mix.
- Qiagen NV (QGEN) expects a slower Q3 with a strong comparable quarter for QuantiFERON, potentially limiting near-term growth.
- The company remains cautious about US funding, noting that NIH outlays are still below prior year levels, which could impact capital sales.
- The strategic review and CEO search create uncertainty, with the transition expected in H2 2026, potentially affecting investor confidence.
- The company did not repurchase shares in Q2 despite a share authorization, which may raise questions about capital deployment priorities.
- Qiagen NV (QGEN) faces increasing competition in the latent TB testing market, though management believes it can maintain market share.
Ladies and gentlemen, thank you for standing by. I am Shelly, your global meet operator. Welcome, and thank you for joining Qiagen's Q2 2026 Earnings Conference Call webcast. (Operator Instructions) Please be advised that the call is being recorded at Qiagen's request and will be made available on the Internet website. (Operator Instructions)
At this time, I would like to introduce your host, Daniel Wendorff, Vice President, Head of Investor Relations at Qiagen. Please go ahead.
&
Thank you, operator, and welcome to our call for the second quarter of 2026. We appreciate your time and interest in Qiagen. Joining the call today are Thierry Bernard, our Chief Executive Officer; and Roland Sackers, our Chief Financial Officer. Also joining us is Dr. Domenica Martorana from our Investor Relations team.
As always, today's call is being webcast live and will be archived in the Investor Relations section of our website at
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
